TGen-led study confirms cell-free DNA in urine as potential method for cancer detection eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail
PHOENIX, Ariz. Jan. 26, 2021 Breast cancer, even at its initial stages, could be detected earlier and more accurately than current techniques using blood samples and a unique proteomics-based technology, according to findings of a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.
Patrick Pirrotte, Ph.D., an Assistant Professor and Director of TGen s Collaborative Center for Translational Mass Spectrometry, and an international team of researchers developed a test that can detect infinitesimally small breast cancer biomarkers that are shed into the bloodstream from cells surrounding cancer known as extracellular matrix (ECM), according to the findings of their study recently published in the scientific journal
E-Mail
The results of a study led by Northern Arizona University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest the immune systems of people infected with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease.
COVID-19 isn t humanity s first encounter with a coronavirus, so named because of the corona, or crown-like, protein spikes on their surface. Before SARS-CoV-2 the virus that causes COVID-19 humans have navigated at least 6 other types of coronaviruses.
The study sought to understand how coronaviruses (CoVs) ignite the human immune system and conduct a deeper dive on the inner workings of the antibody response. The published findings, Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses, appear today in the journal Cell Reports Medicine.
This knowledge could help researchers design new diagnostics, evaluate the healing powers of convalescent plasma, develop new therapeutic treatments, and importantly help design future vaccines or monoclonal antibody therapies capable of protecting against mutations that may occur in the COVID-19 virus. The findings could help explain the widely varying reactions COVID-19 patients have to the disease.
E-Mail
PHOENIX, Ariz. Dec. 15, 2020 The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified a specific genetic target that could help explain the tremendous variation in how sick those infected with COVID-19 become.
The study results, recently published in the journal
mSphere, describe a molecule made from DNA miR1307 as a potential dimmer switch that may influence the severity of the disease; why some infected with SARS-CoV-2, the virus that causes COVID-19, have mild or even no symptoms, while others become seriously ill or die.
Led by Nicholas Schork, Ph.D., a Distinguished Professor and Director of TGen s Quantitative Medicine and Systems Biology Division, researchers identified miR1307 by comparing the genetic elements of SARS-Cov-2 with seven other human coronaviruses, some of which merely cause common colds. In addition, they examined the genomes of coronavirus strains known to infect bats, pigs, pangolins, ferrets, civ